Latest News and Press Releases
Want to stay updated on the latest news?
-
15 % Anstieg der Lizenzeinnahmen 11 % Anstieg der GesamtumsätzeNettoliquidität verdreifacht Phase-3-Programm mit Fosmanogepix verläuft wie geplantGesamtumsatz und Betriebsgewinn 2026: zweistelliges...
-
4Q sales declined q/q by 43% to €12m and FY declined 46% y/y to €132mTotal customer acquisition costs in 4Q were €1m and FY were €28m (-62% y/y)EBITDA for the year 2025 was -€6m (-163%) and -€4m for...
-
TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS Exchange,...
-
Based in New Jersey (USA), to lead ORYZON’s CNS clinical development MADRID and CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a...
-
Zug, 12 February 2026 – Multitude AG, a listed European FinTech company, offering digital lending and online banking services to consumers, small and medium-sized enterprises, and other FinTechs (WKN:...
-
TORONTO, Feb. 11, 2026 (GLOBE NEWSWIRE) -- GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS Exchange,...
-
Exploring the combination with atezolizumab and radiation therapyStudy led by Yale University MADRID, Spain and CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code:...
-
Allschwil, 09. Februar 2026 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren...
-
Allschwil, Switzerland, February 09, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe...
-
Fair Value REIT-AG erwartet Jahresfehlbetrag im HGB-Einzelabschluss für 2025 in Höhe von rund EUR 0,5 Mio. und setzt Dividendenzahlung für 2026 aus